SACRIX, LLC Announces Successful Adoption of Its Revolutionary Bloodless Sacroiliac Fixation Technology At World Leading Academic Center In The USA

Share Article

Sacrix, LLC, a KICVentures Company, invented a new 100% percutaneous posterior sacroiliac joint (SIJ) fixation technique that can be done in less than 20 minutes through a 1.5cm incision in an outpatient setting with no blood loss.

“This threaded device provides compressive stability so there is immediate pain relief” said SacroFuse inventor Professor Dr Kingsley R Chin

Sacrix, LLC, a KICVentures Company, invented a new 100% percutaneous posterior sacroiliac joint (SIJ) fixation technique that can be done in less than 20 minutes through a 1.5cm incision in an outpatient setting with no blood loss.

This new technique for outpatient SIJ fusion uses a pair of patented FDA-cleared threaded cannulated devices that can be placed over a guide wire easily and safely for joint compression that allows for the patient to go home the same day of surgery.

This was the first Sacrix procedure done at this world-leading academic center in the USA as a test case. After the surgery, the neurosurgeon remarked, “Sacrix is the best system for SIJ fusion I have used, it is simple, very easy to use, and straightforward.”

Sacrix has a patented device called SacroFuse which has varying thread configurations to create SIJ compression, a uniquely designed tip that allows for self-drilling and tapping, a threaded inserter that is secured to the implant for insertion and recovery, and a hollow caged cavity that auto-fills with bone graft as the device is inserted. SacroFuse can also be pre-packed and post-packed with flowable NanoFUSE Biologics.

“This threaded device provides compressive stability so there is immediate pain relief” said SacroFuse inventor Professor Dr Kingsley R Chin.

To schedule a Sacrix training and to learn more about this revolutionary technique contact Training@KICVentures.com and visit http://www.KICventures.com to learn more about other outpatient Less Exposure Surgery technologies for the least invasive outpatient spine surgery.

About Sacrix

Sacrix is a safe direct percutaneous outpatient procedure allowing for faster recovery and same day treatment. The posterior approach is indicated for the for the treatment of sacroiliitis and sacroiliac joint disruption. This allows for direct compression and fusion of the sacroiliac joint. The Sacrix SIJ treatment is a least invasive outpatient treatment option. Sacrix is a KICVentures portfolio company

About KICVentures

KICVentures is a private investment holding company founded by Harvard-trained Orthopedic Surgeon & Professor Dr. Kingsley R. Chin, who brings unique experience at the intersection of medicine, business and information technology. KICVentures is equipped with a strong advantage in identifying niche healthcare opportunities and has a proven track-record of building the most disruptive spine technology portfolio, including AxioMed and NanoFUSE Biologics. It has headquarters in Boston, MA

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Vito Lore
Visit website